Department of Primary Care & Population Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
NIHR Collaboration for Leadership in Applied Health Research and Care for Wessex, University of Southampton, Southampton, UK.
NPJ Prim Care Respir Med. 2019 Aug 15;29(1):33. doi: 10.1038/s41533-019-0145-7.
Chronic obstructive pulmonary disease (COPD) is heterogeneous, but persistent airflow obstruction (AFO) is fundamental to diagnosis. We studied AFO consistency from initial diagnosis and explored factors associated with absent or inconsistent AFO. This was a retrospective observational study using patient-anonymised routine individual data in Care and Health Information Analytics (CHIA) database. Identifying a prevalent COPD cohort based on diagnostic codes in primary care records, we used serial ratios of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC%) from time of initial COPD diagnosis to assign patients to one of three AFO categories, according to whether all (persistent), some (variable) or none (absent) were <70%. We described respiratory prescriptions over 3 years (2011-2013) and used multivariable logistic regression to estimate odds of absent or variable AFO and potential predictors. We identified 14,378 patients with diagnosed COPD (mean ± SD age 68.8 ± 10.7 years), median (IQR) COPD duration of 60 (25,103) months. FEV1/FVC% was recorded in 12,491 (86.9%) patients: median (IQR) 5 (3, 7) measurements. Six thousand five hundred and fifty (52.4%) had persistent AFO, 4507 (36.1%) variable AFO and 1434 (11.5%) absent AFO. Being female, never smoking, having higher BMI or more comorbidities significantly predicted absent and variable AFO. Despite absent AFO, 57% received long-acting bronchodilators and 60% inhaled corticosteroids (50% and 49%, respectively, in those without asthma). In all, 13.1% of patients diagnosed with COPD had unrecorded FEV1/FVC%; 11.5% had absent AFO on repeated measurements, yet many received inhalers likely to be ineffective. Such prescribing is not evidence based and the true cause of symptoms may have been missed.
慢性阻塞性肺疾病(COPD)具有异质性,但持续性气流受限(AFO)是诊断的基础。我们研究了从初始诊断开始的 AFO 一致性,并探讨了与不存在或不一致的 AFO 相关的因素。这是一项使用 Care 和健康信息分析(CHIA)数据库中患者匿名常规个体数据的回顾性观察性研究。根据初级保健记录中的诊断代码确定流行的 COPD 队列,我们使用初始 COPD 诊断时的 1 秒用力呼气量与用力肺活量(FEV1/FVC%)的比值来将患者分配到三个 AFO 类别之一,具体取决于是否所有(持续)、某些(变化)或没有(不存在)<70%。我们描述了 3 年(2011-2013 年)的呼吸处方,并使用多变量逻辑回归来估计不存在或可变的 AFO 的可能性以及潜在的预测因素。我们确定了 14378 名患有诊断 COPD 的患者(平均年龄 68.8±10.7 岁),中位(IQR)COPD 持续时间为 60(25,103)个月。在 12491 名(86.9%)患者中记录了 FEV1/FVC%:中位数(IQR)为 5(3,7)次测量。6550 名(52.4%)患者存在持续性 AFO,4507 名(36.1%)患者存在可变 AFO,1434 名(11.5%)患者存在无 AFO。女性、从不吸烟、更高的 BMI 或更多合并症显著预测了无 AFO 和可变 AFO。尽管存在无 AFO,但仍有 57%的患者接受长效支气管扩张剂治疗,60%的患者接受吸入性皮质类固醇治疗(分别为无哮喘患者的 50%和 49%)。在所有患者中,有 13.1%的 COPD 患者未记录 FEV1/FVC%;在重复测量时,有 11.5%的患者存在无 AFO,但许多患者接受了可能无效的吸入器。这种处方不是基于证据的,可能错过了症状的真正原因。